Navigation Links
Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Settlement in Risperdal Marketing Investigation
Date:11/4/2013

New York, NY (PRWEB) November 04, 2013

As Risperdal lawsuits (http://www.therisperdallawsuit.com) involving allegations that use of the antipsychotic drug caused gynecomastia, or male breast growth, continue to mount in courts throughout the country, Bernstein Liebhard LLP notes that Johnson & Johnson has agreed to pay $2.2 billion to settle a government probe into the marketing of some of its drugs, including Risperdal. According to a press release issued today by the U.S. Department of Justice, the settlement includes $4.85 million in criminal fines, and $1.72 billion in civil penalties. Among other things, the agreement resolves charges that Johnson & Johnson misbranded Risperdal and promoted off-label use of the drug for children, elderly nursing home patients, and those with mental disabilities.*

“This news is of great interest to our firm. Like the government, plaintiffs in lawsuits involving Risperdal and gynecomastia have alleged that the drug was improperly marketed to children,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.

Risperdal Lawsuits
Risperdal is approved to treat schizophrenia in adults and adolescents, bipolar disorder in adults and children ages 10-to-17, and to reduce irritability in children (5-to-16 years of age) with autistic disorder.*** Research also indicates that off- label use of Risperdal to treat ADHD is also on the rise.****

Risperdal may cause the body to produce excessive amounts of a hormone called prolactin, according to a 2006 study published in the Journal of Clinical Psychopharmacology. Excessive levels of prolactin were associated with gynecomastia in boys and the development of lactation in girls, according to the study authors. *****

According to a previous report from Bloomberg.com, scores of Risperdal lawsuits have been filed against Johnson & Johnson over allegations that use of the drug can lead to male breast growth. In October 2012, Johnson & Johnson agreed to settle five claims involving Risperdal and gynecomastia that had been filed in Pennsylvania state court. Among other things, the lawsuits alleged that Johnson & Johnson knew use of the drug could lead to male breast development, and that its sales reps were trained to downplay this potential Risperdal side effect. The Plaintiffs also alleged that Risperdal was illegally marketed for use in children.****** (A.B., a minor v. Janssen Pharmaceuticals, 00649, Philadelphia Court of Common Pleas)

According to today’s Bloomberg.com report, the U.S. Justice Department has been probing Risperdal sales practices since 2004, including allegations that the company illegally marketed the drug for use in children and elderly dementia patients.

Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, pain and suffering, emotional distress, and other injury-related damages. Learn More about filing a Risperdal lawsuit at Bernstein Liebhard LLP’s website. For a free case review, please contact the Firm by calling 800-511-5092.

*Justice.gov/opa/pr/2013/November/13-ag-1170.html?source=email_rt_mc_body&app=n, U.S. Department of Justice, November 4, 2013
**bloomberg.com/news/2013-11-04/j-j-settlement-over-risperdal-said-to-be-announced-today.html. Bloomberg.com, November 4, 2013
***accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
****health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
*****journals.lww.com/psychopharmacology/Abstract/2006/04000/Risperidone_induced_Symptomatic.10.aspx, Journal of Clinical Psychopharmacology, April 2006
******Bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 10, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.therisperdallawsuit.com/

Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-male-breast/prweb11300001.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
2. Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
3. The Consumer Justice Foundation Launches RisperdalLaw.com, an Informational Web Site Dealing with Alleged Risperdal Side Effects Including Gynecomastia
4. Parker Waichman LLP Commends Arkansas Attorney General for Backing Fine Against Johnson & Johnson over Risperdal Off-Label Marketing Allegations
5. GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal GranuFlo Recall Litigation
6. Bard IVC Filter Allegation Lawyer Update: Resource4thePeople Reports Additional Lawsuits Claiming IVC Failures Are Filed
7. Da Vinci Robotic Surgery News: Insurance Company's Alleged Concealment of Da Vinci Robot Lawsuits Draws Comment from Wright & Schulte LLC
8. As Another Nine C8 Lawsuits Are Filed, Wright & Schulte Continues to Investigate Cancers allegedly associated with C8 Tainted Water in Ohio and W. Virginia
9. Dozens of Lipitor Lawsuits Involving Diabetes Allegations Moved to Federal Court, Bernstein Liebhard LLP Reports
10. Pradaxa Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance of New Order in Federal Pradaxa Bleeding Litigation
11. Stryker Hip Lawsuit News: Claims in Federal and State Stryker Hip Recall Litigations Surpassed 700 Last Month, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... LLC to help enterprises move workloads to the cloud. Cirracore provides a ... their cloud without traversing the Internet. Transformation Solutions (TSL Partners) provides a ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 ... an appointment after they noticed their furnace not producing any heat. Shortly after entering ... The cracked heat exchanger was leaking dangerous levels of carbon monoxide into the home, ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications collaborated ... Prevention,” an animated video designed to prevent the next widespread Ebola ... video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain Preservation Foundation’s (BPF) ... from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded by recent MIT ... of an intact rabbit brain for extremely long-term storage using a combination of ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... Feb. 9, 2016 The new report "Global Diagnostic Ultrasound ... & Consulting group reveals that global diagnostic ultrasound devices market was ... to US$ 7,466.3 million by 2019 at a CAGR of 6.8% ... global ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
(Date:2/9/2016)... , Feb. 9, 2016 The leader ... that AcceleDent ® is the recipient of the ... category. An FDA-cleared, Class II medical device that speeds ... percent and relieves pain often associated with treatment, AcceleDent ... participated in the annual Orthotown survey of ...
Breaking Medicine Technology: